This study is a European multicentre , randomised , double-blind , placebo-controlled trial investigating the efficacy and safety of nilvadipine as a disease course modifying treatment for mild-to-moderate Alzheimer 's disease ( AD ) in a phase III study that will run for a period of 82weeks with a treatment period of 78weeks .